세계의 요오드 결핍 치료제 시장 규모 조사 : 제형별, 유통 채널별 및 지역별 예측(2022-2032년)

The Global Iodine Deficiency Drug Market is valued approximately at USD 4.14 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.76% over the forecast period 2024-2032. Iodine Deficiency Disorders (IDD) represent a significant public health issue globally, resulting from inadequate dietary intake of iodine, which leads to insufficient thyroid hormone production. This deficiency, known as hypothyroidism, can affect individuals of all ages, genders, and ethnicities, though it is particularly prevalent among women over the age of 60 and children in various countries. Pharmaceutical companies are actively focusing on the development and approval of levothyroxine drugs to meet the increasing demand, particularly in regions with underdeveloped healthcare infrastructure. For instance, in 2021, Zydus Cadila announced that it has received U.S. FDA approval for its thyroid drug for hypothyroidism.

The increasing prevalence of hypothyroidism globally is a key driver propelling the demand for iodine deficiency drugs in the market. Hypothyroidism, characterized by insufficient thyroid hormone production, often results from iodine deficiency, especially in regions where iodized salt intake is inadequate. As awareness grows about the importance of iodine in thyroid function, healthcare providers are diagnosing more cases of hypothyroidism, thereby boosting the need for iodine supplementation therapies. Governments and health organizations are also implementing programs to address iodine deficiency, further stimulating market growth. Pharmaceutical companies are responding with innovative formulations and dosage forms of iodine supplements tailored to different patient demographics and regional needs. This driver underscores the critical role of iodine deficiency drugs in managing thyroid disorders and highlights their increasing importance in public health strategies worldwide. However, side effects associated with levothyroxine, such as irregular heart palpitations, and the need for regular blood tests during pregnancy and in heart patients restrain market growth.

The key region in the Global Iodine Deficiency Drugs Market includes North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2023, the Europe dominates the Global Iodine Deficiency Drugs Market in terms of revenue and expected to grow fastest during the forecast period 2024-2032. This is due to stringent public health measures, widespread iodized salt programs, and high awareness of thyroid disorders. Countries across the region prioritize iodine supplementation to prevent deficiencies, which contribute to thyroid-related health issues like hypothyroidism and goiter. Pharmaceutical companies in Europe focus on developing effective iodine supplements tailored to diverse population needs. The region's proactive approach in healthcare infrastructure and research fosters continuous innovation and ensures high standards of iodine deficiency management. This leadership solidifies Europe's pivotal role in shaping the global market for iodine deficiency drugs.

Major companies operating in the Global Iodine Deficiency Drug Market include

Abbott Laboratories

AbbVie Inc.

Cipla Ltd.

Fresenius SE & Co. KGaA (Fresenius Kabi)

GlaxoSmithKline

Lupin

Macleods Pharmaceuticals

Merck KGaA

Pfizer

Teva Pharmaceutical Industries Ltd., Inc.

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Iodine Deficiency Drug Market Executive Summary

• 1.1. Global Iodine Deficiency Drug Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Dosage Form
  • 1.3.2. By Distribution Channel
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Iodine Deficiency Drug Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Iodine Deficiency Drug Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Increase in Prevalence of Hypothyroidism
  • 3.1.2. Education and Awareness Programs
  • 3.1.3. Increase in Hypothyroidism in Children
• 3.2. Market Challenges
  • 3.2.1. Side Effects of Levothyroxine
  • 3.2.2. Need for Regular Blood Tests
• 3.3. Market Opportunities
  • 3.3.1. Pharmaceutical Interest in Developing Regions
  • 3.3.2. R&D Investments

Chapter 4. Global Iodine Deficiency Drug Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top Investment Opportunity
• 4.4. Top Winning Strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Iodine Deficiency Drug Market Size & Forecasts by Dosage Form 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Iodine Deficiency Drug Market: Dosage Form Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Tablets
  • 5.2.2. Others

Chapter 6. Global Iodine Deficiency Drug Market Size & Forecasts by Distribution Channel 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Iodine Deficiency Drug Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Hospital Pharmacies
  • 6.2.2. Drug Stores and Retail Pharmacies
  • 6.2.3. Online Providers

Chapter 7. Global Iodine Deficiency Drug Market Size & Forecasts by Region 2022-2032

• 7.1. North America Iodine Deficiency Drug Market
  • 7.1.1. U.S. Iodine Deficiency Drug Market
    • 7.1.1.1. Dosage Form breakdown size & forecasts, 2022-2032
    • 7.1.1.2. Distribution Channel breakdown size & forecasts, 2022-2032
  • 7.1.2. Canada Iodine Deficiency Drug Market
• 7.2. Europe Iodine Deficiency Drug Market
  • 7.2.1. U.K. Iodine Deficiency Drug Market
  • 7.2.2. Germany Iodine Deficiency Drug Market
  • 7.2.3. France Iodine Deficiency Drug Market
  • 7.2.4. Spain Iodine Deficiency Drug Market
  • 7.2.5. Italy Iodine Deficiency Drug Market
  • 7.2.6. Rest of Europe Iodine Deficiency Drug Market
• 7.3. Asia-Pacific Iodine Deficiency Drug Market
  • 7.3.1. China Iodine Deficiency Drug Market
  • 7.3.2. India Iodine Deficiency Drug Market
  • 7.3.3. Japan Iodine Deficiency Drug Market
  • 7.3.4. Australia Iodine Deficiency Drug Market
  • 7.3.5. South Korea Iodine Deficiency Drug Market
  • 7.3.6. Rest of Asia Pacific Iodine Deficiency Drug Market
• 7.4. Latin America Iodine Deficiency Drug Market
  • 7.4.1. Brazil Iodine Deficiency Drug Market
  • 7.4.2. Mexico Iodine Deficiency Drug Market
  • 7.4.3. Rest of Latin America Iodine Deficiency Drug Market
• 7.5. Middle East & Africa Iodine Deficiency Drug Market
  • 7.5.1. Saudi Arabia Iodine Deficiency Drug Market
  • 7.5.2. South Africa Iodine Deficiency Drug Market
  • 7.5.3. Rest of Middle East & Africa Iodine Deficiency Drug Market

Chapter 8. Competitive Intelligence

• 8.1. Key Company SWOT Analysis
• 8.2. Top Market Strategies
• 8.3. Company Profiles
  • 8.3.1. Abbott Laboratories
    • 8.3.1.1. Key Information
    • 8.3.1.2. Overview
    • 8.3.1.3. Financial (Subject to Data Availability)
    • 8.3.1.4. Product Summary
    • 8.3.1.5. Market Strategies
  • 8.3.2. AbbVie Inc.
  • 8.3.3. Cipla Ltd.
  • 8.3.4. Fresenius SE & Co. KGaA (Fresenius Kabi)
  • 8.3.5. GlaxoSmithKline
  • 8.3.6. Lupin
  • 8.3.7. Macleods Pharmaceuticals
  • 8.3.8. Merck KGaA
  • 8.3.9. Pfizer
  • 8.3.10. Teva Pharmaceutical Industries Ltd., Inc.

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes